---
title: "Oculis Holding AG (OCS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OCS.US.md"
symbol: "OCS.US"
name: "Oculis Holding AG"
industry: "Pharmaceuticals"
datetime: "2026-06-10T12:01:36.872Z"
locales:
  - [en](https://longbridge.com/en/quote/OCS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OCS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OCS.US.md)
---

# Oculis Holding AG (OCS.US)

## Company Overview

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [oculis.com](https://oculis.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-10T04:30:15.000Z

**Overall: C (0.51)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 77 / 194 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 66.25% |  |
| Net Profit YoY | -1.94% |  |
| P/B Ratio | 2.59 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 636669129.24 |  |
| Revenue | 1411931.39 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -52.66% | E |
| Profit Margin | -8423.51% | E |
| Gross Margin | -6620.57% | E |
| Revenue YoY | 66.25% | A |
| Net Profit YoY | -1.94% | C |
| Total Assets YoY | 31.72% | A |
| Net Assets YoY | 33.28% | A |
| Cash Flow Margin | 66.26% | C |
| OCF YoY | 66.25% | A |
| Turnover | 0.01 | E |
| Gearing Ratio | 19.40% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Oculis Holding AG",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "66.25%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-1.94%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.59",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "636669129.24",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1411931.39",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-52.66%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-8423.51%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-6620.57%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "66.25%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-1.94%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "31.72%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "33.28%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "66.26%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "66.25%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "19.40%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.35 | 167/194 | - | - | - |
| PB | 2.59 | 106/194 | 7.28 | 6.26 | 5.30 |
| PS (TTM) | 450.92 | 159/194 | 1273.09 | 1163.53 | 1053.99 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-03T04:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 73% |
| Overweight | 3 | 27% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.98 |
| Highest Target | 52.78 |
| Lowest Target | 23.02 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/OCS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/OCS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/OCS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/OCS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**